Showing results (491-500 of 532) with videos related to
Sort By:
Pageof 54
Blood Advances|December 19, 2023
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokinesGuido Ghilardi, Luca Paruzzo, Jakub Svoboda, et al.Cancer Discovery|June 5, 2023
Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast CancerNurmaa K Dashzeveg, Yuzhi Jia, Youbin Zhang, et al.Nature Communications|May 15, 2026
Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapyMichael Schneider, Luca Paruzzo, Federico Stella, et al.Cancer Discovery|July 29, 2022
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against CancerYong Gu Lee, Puneeth Guruprasad, Guido Ghilardi, et al.Clinical Lymphoma, Myeloma & Leukemia|April 19, 2023
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International StudyMazyar Shadman, Beenish S Manzoor, Kavita Sail, et al.Lancet (London, England)|February 15, 2026
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 studyM Lia Palomba, Stephen J Schuster, Reem Karmali, et al.Journal of Cellular and Molecular Medicine|October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic LeukaemiaOfrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.The Lancet. Oncology|September 13, 2021
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyStephen J Schuster, Constantine S Tam, Peter Borchmann, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patientsA R Mato, B T Hill, N Lamanna, et al.Iscience|April 22, 2026
Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humansDaniel J Schuster, Shuying S Li, Dieter Mielke, et al.Pageof 54